Objective: Parathyroid carcinoma (PTC) has a high rate of recurrence, which typically occurs within 5 years of diagnosis involving locoregional sites. Immunosuppressive therapies pose a theoretical increased risk of malignancy. We report an atypical case of PTC recurrence in a patient receiving infliximab therapy for ulcerative colitis (UC).
Introduction
Parathyroid carcinoma (PTC) is a rare endocrine neoplasia accounting for ≤5% of primary hyperparathyroidism (PHPT) cases. Recurrence rate following surgery, which is the first-line therapy, can be as high as 49-82%.(1) Typically, PTC recurs within 5 years of initial diagnosis with involvement of the neck or mediastinum, but atypical recurrences occurring as late as 15-20 years have been described (2, 3) . The risk of cancer recurrence may theoretically increase with the use of immunosuppressive therapy, such as tumor necrosis factor α (TNF-α)
antagonist. We report a case of a patient with atypical PTC recurrence in the setting of recently diagnosed ulcerative colitis (UC) and infliximab therapy, which occurred 21 years after the initial diagnosis without obvious locoregional disease. The patient initially presented with nephrolithiasis and hypercalcemia at age 40. He was diagnosed with PHPT and underwent left upper parathyroidectomy. At first, the pathology was reported as parathyroid adenoma. However, after consultation with a nearby academic center, the final diagnosis was revised to PTC given the abundance of mitotic figures and nuclear atypia. He remained asymptomatic with normocalcemia and normal parathyroid hormone (PTH) levels for 21 years.
Case Report
At age 59, he was diagnosed with UC. Given extensive disease, he was prescribed infliximab 1.5 years after the initial diagnosis. A few months later, calcium was found to be elevated at 12.7 mg/dL (normal 8.6-10.3 mg/dL). PTH was inappropriately elevated at 236 pg/mL (normal 14-64 pg/mL). Additional evaluation revealed elevated ionized calcium (7. He underwent video-assisted thoracoscopic surgery (VATS) with excision of the pleural nodules and left lower lobe wedge resection. Pathology was consistent with PTC. Intraoperative PTH levels decreased from 222 to 95 pg/mL, and calcium normalized to 9.8 mg/dL. However, within 5 months hypercalcemia with elevated PTH levels recurred. Given symptomatic hypercalcemia, he was started on cinacalcet. When maximal dose of cinacalcet was no longer effective, zoledronic acid was added. However, hypercalcemia persisted despite increasing frequency of bisphosphonate infusions ( Figure 2 ). Several other therapeutic modalities were considered including denosumab, repeat surgery, chemotherapy, targeted molecular therapy, and immunotherapy as part of a clinical trial. However, genetic analysis of the tumor did not reveal actionable mutations for targeted molecular therapy, and UC precluded participation in a clinical trial. Denosumab was avoided given its potential immunosuppressive effects and possible interaction with UC immunosuppressive therapy, which has been changed to vedolizumab. Since chemotherapy has not been shown to be particularly effective in PTC treatment, he was referred for repeat surgery.
He first underwent repeat VATS with left lower and upper lobe wedge resections, which resulted in minimal improvement of PTH and calcium levels. However, during surgery a cluster of 4 metastases was found along the left diaphragm, which was not well-visualized on prior imaging. He had follow-up debulking surgery with partial left diaphragmatic resection. PTH became undetectable immediately after the surgery with rapid decline in calcium levels. He briefly needed calcitriol and calcium supplements post-operatively. His PTH and calcium levels have remained normal 18 months after his last surgery. This case describes an atypical presentation of PTC recurrence in a patient receiving treatment with infliximab for recently diagnosed UC. PTC is a rare endocrine tumor, accounting for ≤5% of PHPT cases. In contrast to PHPT due to benign adenoma, PTC tends to occur at an earlier age (around age 40-50s) and has equal male and female prevalence. Up to one-third of patients present with regional or distant metastases. The primary treatment modality is surgery.
The recurrence rate after surgery can be as high 49-82% and tends to occur within 5 years of the initial diagnosis with involvement of the neck and/or mediastinum. case, when non-invasive imaging studies are negative or equivocal, selective venous sampling of PTH can aid in localizing metastatic PTC. A study comparing different imaging modalities for detecting recurrent PTC reports the sensitivity of ultrasound, sestamibi scan, CT, MRI, and selective venous sampling with PTH measurements to be 69%, 79%, 67%, 93%, and 83%, respectively. (12) Finally, when the recurrent PTC is unresectable or multiple metastases are present, management of the associated hypercalcemia can be challenging. In fact, hypercalcemia is the most common cause of morbidity and mortality in PTC.(1) Depending on the degree of hypercalcemia, fluids, diuretics, calcitonin, and hemodialysis may be required in the acute setting. Long-term treatment options for hypercalcemia include cinacalcet, intravenous bisphosphonates (pamidronate or zoledronic acid), and denosumab. However, as was seen in this case, hypercalcemia can be progressive and quite recalcitrant to medical therapy. Chemotherapy and radiation in general have not been shown to be effective treatment for PTC, and molecularly targeted cancer therapy and immunotherapy are still considered experimental.(3) In the end, the most effective treatment modality in addressing our patient's recurrent PTC and associated hypercalcemia was repeat surgery.
Conclusion
We report a case of atypical recurrence of PTC that occurred in the setting of immunosuppressive therapy. The presentation is unique in that the recurrence occurred 21 years after the initial diagnosis, and in the absence of locoregional disease. Venous sampling with PTH measurement was helpful in localizing metastatic PTC in this case. Additional surveillance for PTC recurrence may be prudent following initiation of immunosuppressive therapy in patients with history of PTC.
